As a result of intensive prostate-specific testing and screening, extended prostate biopsy schemes and improved imaging techniques, the average age at which prostate cancer is detected in men has decreased by about ten years. Current radical therapies are associated with significant side effects that impair patients’ quality of life. Willemien van den Bos studies a minimally invasive approach to treating prostate cancer, known as focal therapy. In this approach, the malignant areas of the prostate gland are targeted while the benign tissue and vital structures surrounding the prostate are spared.
W. van den Bos: Focal Therapy in Prostate Cancer.
Prof. A.G.J.M. van Leeuwen
Prof. J.J.M.C.H. de la Rosette
Dr D.M. de Bruin
Prof. M.P. Laguna Pes
Dr T.M. de Reijke
This event is open to the public.